Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation

Bone

Volumn 26, Issue 6, 2000, Pages 653-661

  Atkins, G J ^a   Haynes, D R ^a   Geary, S M ^b   Loric, M ^a   Crotti, T N ^a   Findlay, D M ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Cytokine; Hematopoietic cell; Mitochondrial RNA (mRNA); Osteoclast; Stromal cell

Indexed keywords

ACID PHOSPHATASE; ALFACALCIDOL; CALCITRIOL; CYTOKINE; CYTOKINE RECEPTOR; DEXAMETHASONE; RECOMBINANT COLONY STIMULATING FACTOR 1;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CYTOKINE RELEASE; HEMATOPOIETIC CELL; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL;

ANIMALS; BASE SEQUENCE; BONE MARROW CELLS; CELL LINE; CYTOKINES; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MICE; OSTEOCLASTS; RECEPTORS, CYTOKINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STROMAL CELLS;

EID: 0034105329     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(00)00280-5     Document Type: Article

References (36)

1. Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., Teepe M.C., DuBose R.F., Cosman D., Galibert L. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic cell function. Nature. 390:1997;175-179.
2. Fujikawa Y., Quinn J.M.W., Sabokar A., McGee J. O'D., Athanasou N.A. The human osteoclast precursor circulates in the monocyte fraction. Endocrinology. 137:1996;4058-4060.
3. Fuller K., Wong B., Fox S., Choi Y., Chambers T.J. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoblasts. J Exp Med. 188:1998;997-1001.
4. Haynes D.R., Atkins G.J., Loric M., Crotti T.N., Geary S.M., Findlay D.M. Bidirectional signaling between stromal and hematopoietic cells regulates IL-1 expression during human osteoclast formation. Bone. 25:1999;269-278.
5. Haynes D.R., Rogers S.D., Hay S., Pearcy M.J., Howie D.W. The differences in toxicity and release of bone-resorbing mediators induced by titanium and cobalt-chromium-alloy wear particles. J Bone Jt Surg. 75-A:1993;825-834.
6. Haynes D.R., Whitehouse M.W., Vernon-Roberts B. The prostaglandin E1 analogue, misoprostol, regulates cytokines and immune functions in vitro like natural prostaglandins E1, E2 and E3. Immunology. 76:1992;251-257.
7. Hofbauer L.C., Lacey D.L., Dunstan C.R., Spelsberg T.C., Riggs B.L., Khosla S. Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone. 25:1999;255-259.
8. Horwood N.J., Udagawa N., Elliott J., Grail D., Okamura H., Kurimoto M., Dunn A.R., Martin T.J., Gillespie M.T. Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J Clin Invest. 101:1998;595-603.
9. Hsu H., Lacey D.L., Dunstan C.R., Solovyev I., Colombero A., Timms E., Tan H.-L., Elliott G., Kelley M.J., Sarosi I., Wang L., Xia X.-Z., Elliott R., Chiu L., Black T., Scully S., Capparelli C., Morony S., Shimamoto G., Bass M.B., Boyle W.J. Tumor necrosis factor receptor member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA. 96:1999;3540-3545.
10. Jimi E., Shuto T., Koga T. Macrophage colony stimulating factor and interleukin-1α maintain the survival of osteoclast-like cells. Endocrinology. 136:1995;808-811.
11. Jovanovic D.V., Di Battista J.A., Martel-Pelletier J., Jolicoeur F.C., Zhang M., Minéau F., Pelletier J.P. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol. 160:1998;3513-3521.
12. Kotake S., Udagawa N., Takahashi N., Matsuzaki K., Itoh K., Ishiyama S., Saito S., Inoue K., Kamatani N., Gillespie M.T., Martin T.J., Suda T. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. 103:1999;1345-1352.
13. Lacey D.L., Timms E., Tan H.-L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.-X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., Boyle W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93:1998;165-176.
14. 2, interleukin 1α, and tumor necrosis factor-α increase human osteoclast formation and bone resorption in vitro. Endocrinology. 139:1998;3157-3164.
15. Lagasse E., Weissman I.L. Enforced expression of Bcl-2 in monocytes rescues macrophages and partially reverses osteopetrosis in op/op mice. Cell. 89:1997;1021-1031.
16. Martin T.J., Ng K.W. Mechanisms by which cells of the osteoblast lineage control osteoclast formation and activity. J Cell Biochem. 56:1994;357-366.
17. Martin T.J., Romas E., Gillespie M.T. Interleukins in the control of osteoclast differentiation. Crit Rev Eukaryot Gene Expr. 8:1998;107-123.
18. Matsuzaki K., Udagawa N., Takahashi N., Yamaguchi K., Yasuda H., Shima N., Morinaga T., Toyama Y., Yabe Y., Higashio K., Suda T. Osteoclast differentiation factor (ODF) induces osteoclast-like formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun. 246:1998;199-204.
19. Nagai M., Sago N. Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast differentiation factor regulates osteoclast formation. Biochem Biophys Res Commun. 257:1999;719-723.
20. Ng, K. W., Romas, E., Donnan, L., and Findlay, D. M. Bone biology. In: Reid, I. R., Ed. Bailliere's Clinical Endocrinology and Metabolism - Metabolic Bone Disease. London: Balliere Tindall; 1997; 11, 1-22.
21. O'Keefe R.J., Teot L.A., Singh D., Puzas J.E., Rosier R.N., Hicks D.G. Osteoclasts constitutively express regulators of bone resorption An immunohistochemical and in situ hybridization study . Lab Invest. 76:1997;457-465.
22. Paul S., Bennett F., Calvetti J., Kelleher K., Wood C., O'Hara R. Jr, Leary A., Sibley B., Clark S., Williams D., Yang Y. Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic cytokine. Proc Natl Acad Sci USA. 87:1990;7512-7516.
23. Quinn J.M., Elliot J., Gillespie M.T., Martin T.J. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology. 139:1998;4424-4427.
24. Roodman G.D. Advances in bone biology The osteoclast . Endocrine Rev. 17:1996;308-332.
25. Sarma U., Flanagan A.M. Macrophage colony stimulating factor induces substantial osteoclast generation and bone resorption in human bone marrow cultures. Blood. 88:1996;2531-2540.
26. Sato K., Fujii Y., Kasano K., Saji M., Tsushima T., Shizume K. Stimulation of prostaglandin E2 and bone resorption by recombinant human interleukin 1 alpha in fetal mouse bones. Biochem Biophys Res Commun. 138:1986;618-624.
27. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.-S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.-L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P., Sander S., Van G., Tarpley J., Derby P., Lee R., Boyle W.J. Osteoprotegerin A novel secreted protein involved in the regulation of bone density . Cell. 89:1997;309-319.
28. Taga T., Hibi M., Hirata Y., Yamasaki K., Yasukawa K., Matsuda T., Hirano T., Kishimoto T. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell. 58:1989;573-581.
29. Tsuda E., Goto M., Mochizuki S., Yano K., Kobayashi F., Morinaga T., Higashio K. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun. 234:1997;137-142.
30. Udagawa N., Horwood N.J., Elliot J., Mackay A., Owens J., Okamura H., Kurimoto M., Chambers T.J., Martin T.J., Gillespie M.T. Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. J Exp Med. 185:1997;1005-1012.
31. Wani M.R., Fuller K., Kim N.S., Choi Y., Chambers T. Prostaglandin E2 cooperates with TRANCE in osteoclast induction from hematopoietic precursors Synergistic activation of differentiation, cell spreading, and fusion . Endocrinology. 140:1999;1927-1935.
32. Wong B.R., Rho J., Arron J., Robinson E., Orlinick J., Chao M., Kalachikov S., Cayani E., Bartlett F.S., Frankel W.N., Lee S.Y., Choi Y. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem. 272:1997;25190-25194.
33. Yamaguchi K., Kanno T., Murakami A., Tsuda E., Morinaga T., Higashio K. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG) - a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 139:1998;1329-1337.
34. Yasuda H., Shima N., Nakagawa N., Mochizuki S.I., Yano K., Fujise N., Sato Y., Goto M., O'Keefe R.J., Teot L.A., Singh D., Puzas J.E., Rosier R.N., Hicks D.G. Osteoclasts constitutively express regulators of bone resorption An immunohistochemical and in situ hybridisation study . Lab Invest. 76:1997;457-465.
35. Yasuda H., Shima N., Nakagawa N., Mochizuki S.I., Yano K., Fujise N., Sato Y., Goto M., Yamaguchi K., Kanno T., Murakami A., Tsuda E., Morinaga T., Higashio K. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG) - a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 139:1998;1329-1337.
36. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S.-I., Tomoyasu A., Yano K., Goto M., Murakami A., Tsuda E., Morinaga T., Higashio K., Udagawa N., Takahashi N., Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 95:1998;3597-3602.